Pinacidil
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pinacidil
- DrugBank Accession Number
- DB06762
- Background
Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance. The above processes result in reduced blood pressure. This drug has been discontinued by the FDA.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 245.33
Monoisotopic: 245.164045632 - Chemical Formula
- C13H19N5
- Synonyms
- Pinacidil
- Pinacidil anhydrous
- Pinacidilum
- External IDs
- P 1134
- P-1134
- S 1230
- S-1230
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide Abaloparatide may increase the hypotensive activities of Pinacidil. Abametapir The serum concentration of Pinacidil can be increased when it is combined with Abametapir. Acebutolol Acebutolol may increase the hypotensive activities of Pinacidil. Aceclofenac The therapeutic efficacy of Pinacidil can be decreased when used in combination with Aceclofenac. Acemetacin The therapeutic efficacy of Pinacidil can be decreased when used in combination with Acemetacin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Pinacidil monohydrate 7B0ZZH8P2W 85371-64-8 AFJCNBBHEVLGCZ-UHFFFAOYSA-N - International/Other Brands
- Pindac (Leo Pharm)
Categories
- ATC Codes
- C02DG01 — Pinacidil
- C02DG — Guanidine derivatives
- C02D — ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
- C02 — ANTIHYPERTENSIVES
- C — CARDIOVASCULAR SYSTEM
- Drug Categories
- Amidines
- Antihypertensive Agents
- Arteriolar Smooth Muscle, Agents Acting On
- Cardiovascular Agents
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Guanidine Derivatives
- Guanidines
- Membrane Transport Modulators
- Potassium Channel Opener
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridines and derivatives. These are compounds containing a pyridine ring, which is a six-member aromatic heterocycle which consists of one nitrogen atom and five carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Not Available
- Direct Parent
- Pyridines and derivatives
- Alternative Parents
- Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Carboximidamide / Guanidine / Heteroaromatic compound / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BB4UGO5K0D
- CAS number
- 60560-33-0
- InChI Key
- IVVNZDGDKPTYHK-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)
- IUPAC Name
- (Z)-N'-cyano-N-(3,3-dimethylbutan-2-yl)-N''-(pyridin-4-yl)guanidine
- SMILES
- CC(N\C(NC#N)=N\C1=CC=NC=C1)C(C)(C)C
References
- General References
- Hansen PR: [Pinacidil (Pindac). A peripheral vasodilator agent with a new mechanism of action]. Ugeskr Laeger. 1989 Oct 30;151(44):2906-8. [Article]
- Ahnfelt-Ronne I: Pinacidil. Preclinical investigations. Drugs. 1988;36 Suppl 7:4-9. [Article]
- Koliopoulos K, Papadoyannis DE, Karatzas NB: Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension. Eur J Clin Pharmacol. 1984;27(3):287-9. [Article]
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.136 mg/mL ALOGPS logP 2.3 ALOGPS logP 1.94 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 16.28 Chemaxon pKa (Strongest Basic) 8.16 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 73.1 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 73.04 m3·mol-1 Chemaxon Polarizability 27.31 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 159.60783 predictedDeepCCS 1.0 (2019) [M+H]+ 161.96584 predictedDeepCCS 1.0 (2019) [M+Na]+ 168.05899 predictedDeepCCS 1.0 (2019)
Enzymes
1. DetailsCytochrome P450 3A4
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Zhang Z, Li Y, Stearns RA, Ortiz De Montellano PR, Baillie TA, Tang W: Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. Biochemistry. 2002 Feb 26;41(8):2712-8. [Article]
Drug created at September 14, 2010 16:21 / Updated at February 21, 2021 18:52